Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30179% above fair value
$26.68+0.48 (+1.83%)
Close on Nov 13, 2026Market cap $1.72BP/E –Yield –
Stoke Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Stoke Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -753.6%. For fiscal 2025 it was -3.7%, against -243.4% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3.7% | +239.7 |
| FY2024 | Dec 31, 2024 | -243.4% | +949.1 |
| FY2023 | Dec 31, 2023 | -1192.5% | −377.7 |
| FY2022 | Dec 31, 2022 | -814.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -660.8% | −490.8 |
| Q1 FY2026 | Mar 31, 2026 | -802.7% | −873.9 |
| Q4 FY2025 | Dec 31, 2025 | -4132.2% | −4085.9 |
| Q3 FY2025 | Sep 30, 2025 | -360.7% | +179.4 |
| Q2 FY2025 | Jun 30, 2025 | -170.0% | +361.9 |
| Q1 FY2025 | Mar 31, 2025 | 71.2% | +696.8 |
| Q4 FY2024 | Dec 31, 2024 | -46.4% | +915.7 |
| Q3 FY2024 | Sep 30, 2024 | -540.0% | +201.8 |
| Q2 FY2024 | Jun 30, 2024 | -531.9% | −94.3 |
| Q1 FY2024 | Mar 31, 2024 | -625.6% | +159.5 |
| Q4 FY2023 | Dec 31, 2023 | -962.1% | −63.3 |
| Q3 FY2023 | Sep 30, 2023 | -741.9% | +21.1 |
| Q1 FY2023 | Mar 31, 2023 | -437.6% | +384.0 |
| Q4 FY2022 | Dec 31, 2022 | -785.0% | – |
| Q3 FY2022 | Sep 30, 2022 | -898.8% | – |
| Q2 FY2022 | Jun 30, 2022 | -763.0% | – |
| Q1 FY2022 | Mar 31, 2022 | -821.6% | – |
See a number that looks wrong?